Building the Digital Backbone of Global Life Sciences Through Platform-Driven Transformation
Syneos Health has appointed Harpreet Bedi as Senior Vice President & Chief Technology Officer, marking a strategic shift as the company strengthens its digital, data, and platform capabilities across global life-sciences delivery.
As clinical trials, patient engagement, and regulatory systems become increasingly digital-first, Syneos is betting on a CTO who has already built and scaled some of the most complex technology ecosystems in global pharma, healthcare, and enterprise services.
Bedi brings over two decades of experience running large-scale digital platforms, Global Capability Centers (GCCs), and enterprise transformation programs across Big Pharma, clinical research, and global IT services — making him uniquely positioned to power Syneos’ next phase of growth.
A CTO Built for Global Scale, Not Just Systems
Harpreet Bedi is not a conventional CIO-turned-CTO. His career has been forged at the intersection of technology, transformation, and global operations.
Before joining Syneos Health, Bedi spent more than five years at GSK, where he led two of the company’s most important global engines:
- GSK India Global Capability Center (~2,700 professionals)
- GSK Global Poland Hub (~2,300 professionals)
These were not cost centers — they were mission-critical platforms delivering capabilities across:
- R&D
- Supply Chain
- Commercial
- Digital & Technology
- Finance, Legal, Procurement and HR
Simultaneously, Bedi ran GSK’s Enterprise Transformation Office (ETO) — the organization responsible for industrializing change using:
- Program & portfolio management
- Process excellence
- Data & analytics
- Change management
- AI, automation and GenAI
Few technology leaders have had this level of end-to-end ownership over digital execution inside a Fortune-50 pharma company.
From Digital Strategy to Digital Factories
Earlier, as Global Head of Digital & Technology Strategy & Performance at GSK, Bedi sat on the CDTO’s leadership team, driving enterprise-wide digital acceleration.
He led:
- GSK’s Digital Accelerator (AI, Data, Cybersecurity, Product, Design Thinking)
- Global Strategic Partner Program across 11 technology partners
- Digital capability building across R&D, supply chain, and commercial operations
In parallel, he built Poland into a multi-function global hub delivering enterprise-wide digital and operational capability.
This combination — strategy + skills + delivery + platforms — is exactly what Syneos Health now requires as it scales digitally across the drug-development lifecycle.
IQVIA: Running the World’s Clinical Technology Engines
Before GSK, Bedi served as Division CIO & Global Head of IT for R&D Solutions at IQVIA, one of the world’s largest clinical research organizations.
There, he was responsible for:
- Global technology platforms supporting clinical trials in 100+ countries
- Big-data pipelines for patient and trial data
- Advanced analytics
- Cloud-enabled platforms
- Automation to reduce drug-development cycle times
This wasn’t internal IT — these were market-facing digital products that directly powered how pharma companies brought medicines to market.
The Accenture + Microsoft Foundation
Earlier in his career, Bedi built his leadership muscle at:
- Accenture — running multi-country health, public sector, and digital transformation programs across EALA and emerging markets
- Microsoft — managing large-scale service delivery, vendor ecosystems, and 24×7 global operations
These experiences shaped him into a CTO who understands:
- Platform reliability
- Regulatory environments
- Global delivery
- Enterprise-grade governance
What His Appointment Means for Syneos Health
Syneos is rapidly evolving from a services-led CRO into a technology-enabled life-sciences platform.
Bedi’s background positions him to:
- Build AI-driven clinical and patient platforms
- Strengthen data, analytics, and automation
- Scale digital delivery through global hubs
- Create resilient, compliant, cloud-native ecosystems
- Integrate R&D, operations, and commercial tech stacks
In short, he is here to turn technology into Syneos’ competitive advantage.
CXO Gateway Reflection
At CXO Gateway, we see Harpreet Bedi’s appointment as a powerful signal of where life sciences is headed.
This is not about maintaining IT.
This is about engineering the digital infrastructure of global drug development.
Harpreet Bedi represents a new generation of CTOs — leaders who build platforms, ecosystems, and digital factories that allow science to move faster, smarter, and at global scale.